Company news

Xeris Biopharma Holdings, Inc. news in 2026

Xeris Biopharma Holdings, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Quarterly Report for Quarter Ending September 30, 2026 (Form 10-Q)

November 5, 2026

Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights

November 5, 2026

Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors

November 2, 2026

Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

October 22, 2026

Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings

October 15, 2026

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

October 2, 2026

medmix' Drug Delivery ("Haselmeier") to Support the Development of Xeris Pharmaceuticals' XP-8121 with D-Flex(TM) Pen Injector

September 10, 2026

Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism

September 9, 2026

Xeris Announces Details for XP-8121 Program Overview Webinar

August 26, 2026

Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)

August 6, 2026

Xeris Biopharma Reports Second Quarter 2026 Financial Results

August 6, 2026

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

July 23, 2026

CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

July 2, 2026

Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

July 2, 2026

Xeris Announces Updates to Its Board of Directors

June 30, 2026

Xeris Biopharma Announces Private Exchange of Convertible Notes

June 11, 2026

Xeris Biopharma Reports First Quarter 2026 Financial Results

May 7, 2026

Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026

April 23, 2026

Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance

March 1, 2026

Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit

February 26, 2026

Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026

February 17, 2026

Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue

January 7, 2026

Calls in 2026

Decks in 2026